Cannabinoid News and Research

Latest Cannabinoid News and Research

GW Pharmaceuticals to expand marketing authorization for Sativex to France

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that it has submitted an application under the European Mutual Recognition Procedure seeking to expand the marketing authorization for Sativex into France for the treatment of spasticity due to Multiple Sclerosis.

22 Jul 2013

Neutra's MMJ subsidiary forms joint venture to market, develop cannabis delivery systems

In a major step forward in its plans to deliver healthier, more effective innovations to the fast-growing medical marijuana industry in the U.S., Neutra Corp. announced today that its MMJ subsidiary, Cannabis Technologies, Inc., has formed a new joint venture with Field of View Technologies, LLC, to market and develop breakthrough cannabis delivery systems.

5 Jun 2013

Report finds increase in unintentional marijuana ingestions among young children

Following modification of drug enforcement laws for possession of marijuana in Colorado, there was an apparent increase in unintentional marijuana ingestions by young children, according to a report and accompanying editorials published Online First by JAMA Pediatrics, a JAMA Network publication.

28 May 2013

Neutra in final stages of negotiations toward new partnership in U.S. MMJ industry

Neutra Corp., a growing provider of all-natural wellness solutions, announced today that it has entered the final stages of negotiations toward a potentially lucrative new partnership in the $1.7 billion U.S. medical marijuana industry.

14 May 2013

Researchers discover connection between CB1 receptors and PTSD

In a first-of-its-kind effort to illuminate the biochemical impact of trauma, researchers at NYU Langone Medical Center have discovered a connection between the quantity of cannabinoid receptors in the human brain, known as CB1 receptors, and post-traumatic stress disorder, the chronic, disabling condition that can plague trauma victims with flashbacks, nightmares and emotional instability.

14 May 2013

New bill could open up new territory for MMJ innovations

As Neutra Corp. works to deliver new innovations making medical marijuana safer and more effective than ever before, the market for such breakthroughs is expanding rapidly. Just last month, two new state legislatures—Pennsylvania and Alabama—saw favorable cannabis bills formally introduced.

8 May 2013

Neuroscientists identify cellular change in the brain that accompanies obesity

A team of American and Italian neuroscientists has identified a cellular change in the brain that accompanies obesity. The findings could explain the body's tendency to maintain undesirable weight levels, rather than an ideal weight, and identify possible targets for pharmacological efforts to address obesity.

30 Apr 2013

Modulation of cerebral endocannabinoid system may help treat Fragile X chromosome syndrome

Researchers at the University of the Basque Country (UPV/EHU) and the Achucarro neurosciences centre have discovered a new therapy for the fragile X chromosome syndrome. This new therapy proposes the modulation of the cerebral endocannabinoid system in order to ameliorate the symptoms of the disease.

11 Apr 2013

Neutra explores smokeless delivery methods for marijuana users

Could the future of medical marijuana be smoke-free? As the market for medicinal cannabis booms across the U.S., Neutra Corp., a provider of all-natural health solutions, is exploring the potential of vaporizers, sprays, edibles, and other smokeless delivery methods to enable marijuana users to enjoy the benefits without the potential side effect of lung damage.

1 Apr 2013

CB2 receptors might serve as potential therapeutic targets for cerebral ischemia

A new study published in the March issue of The American Journal of Pathology suggests that cortical type 2 cannabinoid (CB2) receptors might serve as potential therapeutic targets for cerebral ischemia.

22 Feb 2013

Agilent launches new application compendiums on designer drug testing and toxicology of oral fluids

Agilent Technologies Inc. today introduced new application compendiums on designer drug testing and toxicology of oral fluids.

5 Feb 2013

Acetaminophen may improve postoperative outcomes

Prophylactically administered intravenous acetaminophen could reduce postoperative nausea and vomiting, research suggests.

16 Jan 2013

e-Therapeutics’ ETS2101 cancer trials on track

e-Therapeutics plc today provides an update on the clinical trials of its cancer drug ETS2101. Two phase I studies, one in patients with primary or secondary brain cancer and the other in patients with various solid tumours, remain on track to report final data in Q4 2013 and Q1 2014, respectively. Interim data from the trials are expected in H1 2013.

18 Dec 2012

Synthetic marijuana linked to 11,406 of 4.9M drug-related ED visits in 2010

Street forms of synthetic cannabinoids - so-called "synthetic marijuana" - were linked to 11,406 of the 4.9 million drug-related emergency department (ED) visits in 2010, according to a new report by the Substance Abuse and Mental Health Services Administration (SAMHSA).

6 Dec 2012

‘Pain as reward’ raises tolerance threshold

An individual’s ability to tolerate pain is influenced by their preconceptions and beliefs about the meaning of the pain, Italian researchers have shown.

5 Dec 2012

Synthetic cannabinoid could treat pain in diabetes patients

Oral synthetic cannabinoid nabilone may be effective for treating diabetic peripheral neuropathic pain, a study shows.

8 Nov 2012

Study identifies monoacylglycerol lipase as new therapeutic target to treat Alzheimer's

Research led by Chu Chen, PhD, Associate Professor of Neuroscience at LSU Health Sciences Center New Orleans, has identified an enzyme called Monoacylglycerol lipase (MAGL) as a new therapeutic target to treat or prevent Alzheimer's disease.

2 Nov 2012

Scientists discover first selective inhibitors of DAGL enzymes

Scientists at The Scripps Research Institute (TSRI) have discovered the first selective inhibitors of an important set of enzymes. The new inhibitors, and chemical probes based on them, now can be used to study the functions of enzymes known as diacylglycerol lipases (DAGL), their products, and the pathways they regulate.

1 Nov 2012

Nabilone shows promise in treating diabetic neuropathy

A study from the University of Calgary's Hotchkiss Brain Institute shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain.

31 Oct 2012

Link between marijuana use and cannabinoid hyperemesis

Marijuana use-both natural and synthetic-may cause cannabinoid hyperemesis (CH) a little-known but costly effect that researchers suggest is a serious burden to the health care system as it often leads to expensive diagnostic tests and ineffective treatments in an effort to find the cause of a patient's symptoms and provide relief, according to two separate case reports unveiled today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas.

23 Oct 2012